Biota are by far the most experienced company in the world in terms of influenza antivirals and they have a 3rd gen flug drug - FLUNET - in development...although it is still in pre-clinical...
...I hope Biota management rethink their strategy of sitting on FLUNET rather than advancing its development at good pace. Stalling it at pre-clinical rather than say, prior to Phase 3 (where trials are the most costly) is complacent at best and at worst, an arrogant approach - LANI will not have the market to itself forever and with developments by companies like Vertex, it is important not to assume that its all too far off to worry about. If they are simply worried about FLUNET cannibalising LANI sales because it is ready to sell before LANI has maximised all opportunities, they are living in dream world.
Case in point - there will be a 2-3 year gap between Relenza coming off patent and commercialisation of LANI...have they learned from their mistakes?
Say no more.
Add to My Watchlist
What is My Watchlist?